# Sinopharm Capital

> Sinopharm Capital is a VC fund backing Health Care and Biotechnology. See 50 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 50
- Last investment: Nov 2025
- Lead investor: 38%
- Fund size: $150M
- Last fund: Jun 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/sinopharm-capital-%E5%9B%BD%E8%8D%AF%E8%B5%84%E6%9C%AC/
- Website: http://www.sinopharmcapital.com/

Sinopharm Capital is a private equity arm of China National Pharmaceutical Group Corporation that specializes in medical and healthcare, pharmaceuticals, biotechnology, medical devices, healthcare and medical supply, and services for elderly and persons with disability. It seeks to invest in China. Sinopharm Capital was founded in June 2012 and isbased in Shanghai, China.

## Contacts

5 contacts available for Sinopharm Capital. Shizune tracks 6 team members at Sinopharm Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sinopharm-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2.9M–$16M |
| Series A | $1.4M–$28M |
| Series B | $9.2M–$114M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 30 | 60% |
| Biotechnology | 20 | 40% |
| Medical | 13 | 26% |
| Pharmaceutical | 11 | 22% |
| Biopharma | 5 | 10% |

30 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 14 | 28% |
| Series B | 13 | 26% |
| Seed | 5 | 10% |
| Series C | 5 | 10% |
| Angel | 4 | 8% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 38 | 76% |
| United States | 5 | 10% |
| Canada | 1 | 2% |
| Hong Kong | 1 | 2% |
| Singapore | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Aimin Wu | President | 1 | https://shizune.co/investors/profile/aimin-wu |
| Fei Jiang | Executive Vice-President | 0 | https://shizune.co/investors/profile/fei-jiang |
| Shengtao Zhu | Managing Director | 0 | https://shizune.co/investors/profile/shengtao-zhu |
| Xiaoming Yang | Managing Director | 1 | https://shizune.co/investors/profile/xiaoming-yang |
| Yong Kuang | Managing Director | 0 | https://shizune.co/investors/profile/yong-yong |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Jinju Biopharmaceuticals | Jinju Biotechnology is a high-tech enterprise specializing in the research and development of stem cell therapies. |  | Series A | Nov 19, 2025 |  |
| Artivila Therapeutics | Artivila Therapeutics is a pharmaceutical company focused on improving patient's lives through an AI-powered drug discovery engine. The company is committed to discover the best therapeutical solutions to neuro-degenerative diseases, cancers, and autoimmune diseases empowered with an integrated AI-driven innovative drug discovery platform,providing first-in-class new molecules consistently and efficiently.Artivila Therapeutics was founded in 2018 and is based in ShenZhen, China. | $15.8M | Seed | Mar 31, 2022 |  |
| Metanovas Biotech | Metanovas is a metabolic drug developer focused on combining artificial intelligence with life sciences, using deep learning. | $10M | Seed | Mar 30, 2022 |  |
| Metanovas Biotech | Metanovas is a metabolic drug developer focused on combining artificial intelligence with life sciences, using deep learning. | $10M | Seed | Mar 30, 2022 |  |
| CytoNiche | CytoNiche focuses on the development of 3D micro-organization engineering technology. The core technology is derived from the transformation of Tsinghua University's achievements. Based on its original research technology, Huasheng Bio has launched a series of related products and services, including customized, large-scale, automated andintelligent stem cell culture. Amplification process; 3D stem cell micro-tissue regeneration treatment of new drugs and 3D cell high-throughput drug screening products. | $47.5M | Series B | Mar 03, 2022 |  |
| Xishan | Xishan is a surgical equipment and consumables manufacturing company. | $15.7M | Series D | Dec 13, 2021 |  |
| Sumgen Biotech | Jianjian Biotechnology is an antibody drug developer, specializing in the development of therapeutic antibody drugs and the application of antibodies in immunotherapy and immunodiagnosis. Based on CD&MD innovative antibody research and development technology, it has developed products such as tumor immunotherapy antibody drugs and CARTantibodies. . |  |  | Dec 07, 2021 |  |
| Sumgen Biotech | Jianjian Biotechnology is an antibody drug developer, specializing in the development of therapeutic antibody drugs and the application of antibodies in immunotherapy and immunodiagnosis. Based on CD&MD innovative antibody research and development technology, it has developed products such as tumor immunotherapy antibody drugs and CARTantibodies. . |  | Series B | Dec 07, 2021 |  |
| Longhui Medical | Longhui Medical is a medical robotics R&D company focused on joint replacement surgery robots, product development, sales, and service. | $15.6M | Series B | Nov 26, 2021 |  |
| Sepax Technologies | Sepax Technologie is a biotechnology firm that offers ion exchange, hydrophobic interaction, and method development services. | $78.3M | Series D | Nov 15, 2021 |  |

10 of 50 investments shown.

## Co-investors
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 4 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 4 deals together
- [Addor Capital](https://shizune.co/investors/profile/addor-capital) — VC Fund, 3 deals together
- [CDH Investments](https://shizune.co/investors/profile/cdh-investments) — VC Fund, 3 deals together
- [Jinyi Capital](https://shizune.co/investors/profile/jinyi-capital-9c2c) — VC Fund, 3 deals together
- [Pan-Lin Capital](https://shizune.co/investors/profile/pan-lin-asset-management) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Health Care Investors in Asia](https://shizune.co/investors/health-care-investors-asia)
- [Health Care VC Funds in Asia](https://shizune.co/investors/health-care-vc-funds-asia)
- [Health Care Investors in China](https://shizune.co/investors/health-care-investors-china)
- [Health Care VC Funds in China](https://shizune.co/investors/health-care-vc-funds-china)
- [Biotechnology Investors in China](https://shizune.co/investors/biotechnology-investors-china)
- [Biotechnology VC Funds in China](https://shizune.co/investors/biotechnology-vc-funds-china)

## FAQ

### What does Sinopharm Capital invest in?

Sinopharm Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 50 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Sinopharm Capital's check size?

Sinopharm Capital typically joins rounds of $2.9M–$16M at Seed, $1.4M–$28M at Series A and $9.2M–$114M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sinopharm Capital participates in.

### How do I contact Sinopharm Capital?

Public channels for Sinopharm Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sinopharm Capital?

The team at Sinopharm Capital includes Aimin Wu (President), Fei Jiang (Executive Vice-President) and Shengtao Zhu (Managing Director), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co